Michael Hedvat | Director
Xencor, Inc.

Festival of Biologics Day 2 @ 14:30

Harnessing Protein Engineering to Modulate Immune Responses via CD28 Costimulatory Pathways

T cells require T-cell receptor engagement by peptide-major histocompatibility complexes coupled with CD28-mediated costimulation for optimal activation. Tumor cells typically lack expression of CD28 ligands, so we hypothesized that CD28 signaling at the T cell/tumor cell interface could enhance anti-tumor activity. We generated tumor-associated antigen (TAA) x CD28 bispecific antibodies that provide CD28 costimulation only in the presence of TAA and TCR engagement and show enhanced activity over traditional bispecifics.

Michael Hedvat, Director, Xencor, Inc.

×

Michael Hedvat / Harnessing Protein Engineering to Modulate Immune Responses via CD28 Costimulatory Pathways

Michael Hedvat, Director,
Xencor, Inc.

Michael Hedvat is Director of Discovery Bioloy at Xencor, Inc., where he leads development of novel therapeutics in oncology and autoimmunity. Prior to joining Xencor, Dr. Hedvat was a research scientist in the translational oncology group at Kyowa Hakko Kirin, CA. He received his B.S. at...

CloseMore